<DOC>
	<DOCNO>NCT01507285</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial ass safety tolerability ( maximum tolerate dose ) single multiple dos NNC 90-1170 ( liraglutide ) healthy volunteer subject type 2 diabetes .</brief_summary>
	<brief_title>Safety Tolerability Liraglutide Healthy Volunteers Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>HEALTHY VOLUNTEERS Healthy subject age 1845 year inclusive Healthy subject define individual free significant cardiac , pulmonary , gastrointestinal , hepatic , renal , haematological , neurological psychiatric disease determine history , physical examination clinical laboratory test result Women childbearing potential Signed date write informed consent obtain Body mass index ( BMI ) within range 1930 kg/m^2 , inclusive SUBJECTS WITH DIABETES Subjects age 4070 year inclusive Subjects diagnose type2 diabetes duration diabetes 12 month Women childbearing potential Signed date write informed consent obtain Fasting Cpeptide least 0.3 nmol/l blood glucose least 7 mmol/l Subjects currently diet and/or OHA ( oral hypoglycemic agent ) least six month Body mass index ( BMI ) 35 kg/m^2 HbA1c ( glycosylated haemoglobin ) 11 % Stable current medication least 3 week prior dose study HEALTHY VOLUNTEERS Clinically relevant abnormal history physical finding ( e.g . cancer ) screen assessment , could interfere objective study safety subject 's participation Clinically relevant abnormality laboratory value ECG screen evaluation Presence acute chronic illness sufficient invalidate subject 's participation study make unnecessarily hazardous Blood pressure heart rate seat position screen examination outside range 90150 mmHg systolic , 4090 mmHg diastolic : heart rate 40100 beats/min History drug alcohol abuse ( alcohol abuse define intake 28 unit weekly men 21 unit weekly woman ) Alcohol intake within 48 hour prior visit Evidence drug abuse urine test study entry The subject smoke 10 cigarette , equivalent , per day unable refrain smoke 3 day prior first dose day confinement period Hepatitis B surface antigen ( HBsAg ) , Hepatitis C antibody HIV ( human immunodeficiency virus ) antibodies History significant drug allergy drug hypersensitivity SUBJECTS WITH DIABETES Use drug ( except oral hypoglycaemic agent ( OHAs ) ) Investigator 's opinion could interfere blood glucose level ( e.g . insulin , systemic corticosteroid , thiazide ) Recurrent severe hypoglycaemia judge Investigator Clinically relevant abnormal history physical finding ( e.g . cancer ) screen assessment , could interfere objective study safety subject 's participation Clinically relevant abnormality laboratory value ECG screen evaluation Presence acute chronic illness sufficient invalidate subject 's participation study make unnecessarily hazardous Blood pressure heart rate seat position screen examination outside range 110160 mmHg systolic , 6090 mmHg diastolic : heart rate 40100 beats/min History drug alcohol abuse ( alcohol abuse define intake 28 unit weekly men 21 unit weekly woman ) Alcohol intake within 48 hour visit Evidence drug abuse urine test study entry The subject smoke 10 cigarette , equivalent , per day unable refrain smoke 3 day prior first dose day confinement period Hepatitis B surface antigen ( HBsAg ) , Hepatitis C antibodies History significant drug allergy drug hypersensitivity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>